Mr. Donovan has served as President and Chief Executive Officer since joining the company in 2016. He brings more than two decades of industry experience, including senior leadership roles within several biotechnology companies, as well as corporate finance advisory and transaction execution in investment banking. Prior to joining Tioma, Mr. Donovan was co-founder of Alios BioPharma and served as its Chief Business Officer and Chief Financial Officer from January 2011 through its acquisition by Johnson & Johnson (November 2014) until December of 2015. Prior, he served as Chief Financial Officer of CoMentis, a privately held biotechnology company and as head of Strategic Planning & Corporate Communications at InterMune, a publicly traded biotechnology company (subsequently acquired by Roche). Mr. Donovan began his career at Vector Securities International, a boutique life sciences investment bank, then at Banc of America Securities, a global, full-service investment bank. He received his Bachelors of Business Administration from the University of Notre Dame.
President and Chief Executive Officer
Pankaj Bhargava, M.D.
Chief Medical Officer
Dr. Bhargava has acted as Chief Medical Officer since 2016. He brings a broad range of clinical experience as a medical oncologist and clinical pharmacologist. Dr. Bhargava has been involved in drug development over two decades, including leadership roles in biotech and pharmaceutical companies, overseeing clinical development, pharmacovigilance, regulatory affairs and medical affairs. Prior to joining Tioma, he was Chief Medical Officer at Dicerna Pharmaceuticals where he was responsible for development across all therapeutic areas including oncology and rare diseases. Previously, he was Associate Vice President at Sanofi Oncology, where he led the global development of Zaltrap™ (aflibercept), culminating in successful approvals by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and multiple agencies worldwide. Prior to Sanofi, Dr. Bhargava was vice president of clinical research and interim Chief Medical Officer at AVEO Pharmaceuticals. He currently serves as an attending physician at Dana-Farber Cancer Institute and is an Assistant Professor at Harvard Medical School. Dr. Bhargava received his M.D. from University College of Medical Sciences, Delhi University. He is U.S. Board Certified in Internal Medicine, Medical Oncology and Clinical Pharmacology, and completed an advanced fellowship in Developmental Therapeutics at the Lombardi Cancer Center at Georgetown University, during which he served as a visiting fellow at the FDA Center for Drug Evaluation and Research (CDER).
Robert W. Karr, M.D.
Chief Scientific Officer
Dr. Karr is currently Tioma’s Chief Scientific Officer, a position he has held since 2016. He joined the company in 2010, serving as its first Chief Executive Officer. Dr. Karr brings extensive experience in the pharmaceutical and biotechnology industries with expertise ranging the spectrum of drug development, from discovery research to clinical trial execution. Prior to Tioma, Dr. Karr held senior management positions in Idera, Pfizer, and Warner-Lambert. Dr. Karr completed his internship and residency in internal medicine at Washington University School of Medicine and served as faculty member at both the University of Iowa College of Medicine and Washington University School of Medicine. He received his B.S. from Southwestern University and his M.D. from the University of Texas Medical Branch.
Sanjay Chanda, Ph.D.
Chief Development Officer
Dr. Chanda joined Tioma in 2016 and serves as its Chief Development Officer. He brings more than twenty years of experience in drug development, including product development, regulatory affairs, and product registration. Most recently, Dr. Chanda served as Senior Vice President, Drug Development at Anacor Pharmaceuticals until its acquisition by Pfizer in June of 2016. At Anacor, he was responsible for all aspects of CMC and Preclinical Safety and played key leadership roles in the development and approvals of KERYDIN® for the treatment of onychomycosis and EUCRISA® for the treatment of eczema. Previously, Dr. Chanda was Senior Director, Toxicology, Drug Metabolism and Pharmacokinetics at NeurogesX, Inc., prior to its acquisition by Acorda Therapeutics, where he played a leadership role in development of QUTENZA® for the management of neuropathic pain associated with postherpetic neuralgia. He also held leadership positions at Cerus Corporation and PPD-Development. Dr. Chanda has over thirty publications in various peer-reviewed journals. He received his Ph.D. in Pharmacology/Toxicology at Northeast Louisiana University and completed postdoctoral fellowships at University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina.
Chief Business Officer
Mr. Stutz has served as Chief Business Officer of Tioma since joining the company in 2016. He has over 15 years of experience in the life sciences industry in operations, venture capital and management consulting positions. Prior to joining Tioma, Mr. Stutz was Vice President of Strategy & Business Development at Alios BioPharma (acquired by Johnson & Johnson in 2014) where he was responsible for business development, strategic and financial planning. Before joining Alios, he was a Principal at Essex Woodlands, where he worked on numerous venture capital and growth equity transactions in the biopharmaceutical and life science tools space. He also held various business development, finance and planning positions at CoMentis and InterMune. Earlier in his career Mr. Stutz was a Senior Consultant at Strategic Decisions Group and was a commissioned officer in the United States Air Force. He holds an M.B.A. from the Tuck School of Business at Dartmouth and a B.A. in Business Economics from the University of California, Santa Barbara. Since October 2012, he has held an appointment as a Lecturer at Stanford University in the Department of Medicine, Division of Clinical Pharmacology in the School of Medicine.
Pamela T. Manning, Ph.D.
Vice President of Research
Dr. Manning has served as Vice President of Research since co-founding Tioma in 2006. She has over 20 years of experience in drug discovery within the pharmaceutical industry including positions at G.D. Searle, Pharmacia and Pfizer. Dr. Manning has considerable experience developing drug candidates from discovery through IND-enabling studies and early clinical development. Her broad expertise in pharmacology spans multiple therapeutic areas including neuroscience, cardiovascular, oncology, inflammation and pain. She is also internationally recognized in the field of nitric oxide research. Dr. Manning received her Ph.D. in Pharmacology from the Ohio State University, completed postdoctoral studies in pharmacology at Washington University School of Medicine and holds an M.S. and B.S. from Wright State University.
Vice President of Clinical Operations
Mr. Hinds has served as Vice President of Clinical Operations since joining Tioma in 2016. He was previously Senior Director of Clinical Operations at Alios Biopharma (acquired by Johnson and Johnson in 2014). Mr. Hinds has more than 21 years of experience focused on the delivery of clinical programs across all phases of development and multiple therapeutic areas. He has held a variety of positions with small and large clinical research organizations as well as small and large pharma and biotech firms. He has directly contributed to the success of global products including Rituxan, Adcetris, and Velcade. He received an M.B.A from the Darla Moore School of Business at the University of South Carolina and a B.S. in Biology from the Citadel.
Catherine Tribouley, Ph.D.
Vice President of Translational Development
Dr. Tribouley is a translational medicine expert with over two decades of combined clinical research experience in immune-oncology and genomics application. Prior to joining Tioma, she held various leadership and senior research positions at multiple pharmaceutical companies spanning the specialties of heme-oncology, immune-oncology, inflammation and tumor angiogenesis. Most recently, Dr. Tribouley served as a Senior Global Correlative Sciences Leader and Senior Director for the Cell and Gene Therapy unit at Novartis. Previously, she was an Expert Scientist in Translational Research Science at Roche Pharmaceuticals. Dr. Tribouley also held various scientific positions at Merck Research Laboratories, Gene Logic, Cytokinetics, Incyte Genomics, and Chiron Corporation. She received a Ph.D. joint degree in Molecular Biology and Virology from the University of Lyon and IGBMC and an M.S. in Biochemistry from the University of Paris VII.
William A. Frazier, Ph.D.
Scientific Founder and Advisor
Dr. Frazier is a professor of Biochemistry, Molecular Biophysics, and Cell Biology at Washington University School of Medicine. He discovered that CD47 is a receptor for thrombospondin-1. Having contributed to over 140 publications, Dr. Frazier has been a leader in the field of CD47-mediated signaling pathways for many years. He founded Tioma (formerly Vasculox) in 2006 based on research from his laboratory and that of his collaborators at the National Institutes of Health. Dr. Frazier holds a B.A. from Johns Hopkins University and a Ph.D. from Washington University in St. Louis.